Navigation Links
Sorrento Therapeutics and IGDRASOL to Present Late Stage Clinical Data Updates on their Oncology Nanomedicine Platform at the Joint Meeting of the European Foundation for Clinical Nanomedicine and European Technology Platform on Nanomedicine in Base
Date:6/21/2013

mprop="name">Kouros Motamed, Chulho Park and Catherine Cheng.

About Sorrento Therapeutics

Sorrento Therapeutics, Inc. is a publicly-traded, development-stage biopharmaceutical company engaged in the acquisition, discovery, development and commercialization of proprietary drug therapeutics for addressing significant unmet medical needs in the Unites States, Europe and additional international markets. Sorrento Therapeutics' primary therapeutic focus is oncology but it is also developing therapeutics products for other indications, including inflammation, metabolic, and infectious diseases. Sorrento Therapeutics' proprietary G-MAB® fully-human antibody library platform was designed to facilitate the rapid identification and isolation of highly specific antibody therapeutic product candidates that bind to disease targets appropriate for antibody therapy. 

More information is available at www.sorrentotherapeutics.com.

About IGDRASOL

IGDRASOL's lead therapeutic platform is Cynviloq™, a branded micellar paclitaxel formulation which is free of cremophor and human serum albumin, the excipients for Taxol® (cremophor-based paclitaxel) and albumin-bound paclitaxel (Abraxane®), respectively. Cynviloq™ combines the simplicity of manufacturing and preparation of Taxol® and potentially the albumin-mediated transport of paclitaxel. IGDRASOL intends to conduct registration trials for multiple cancer indications.  

The executives of IGDRASOL are a group of pharmaceutical veterans who believe that personalized paclitaxel nanoparticle therapy will present a paradigm shift in the delivery of chemotherapeutic agents.  To learn more about IGDRASOL's mission, please visit its website (http://www.igdrasol.com).

'/>"/>
SOURCE Sorrento Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Sorrento Therapeutics Receives Frost & Sullivans Prestigious 2013 Global Investment Opportunity Award in the Oncology Market
2. Sorrento Therapeutics Receives Frost & Sullivans 2013 Global Investment Opportunity Award in Oncology
3. Sorrento Therapeutics to Present at the Jefferies 2013 Global Healthcare Conference in New York City
4. Sorrento Therapeutics, Inc. announces its approach to developing human antibody therapeutics against MRSA receives continued support from the National Institute of Allergy and Infectious Diseases
5. Sorrento Therapeutics, Inc. and IGDRASOL Announce Presentation on Non-Biologic Nanoparticle paclitaxel (NBN-Pac) Formulations for the Treatment of Solid Tumors at the Nanomedicine 2013 Meeting in Barcelona, Spain
6. Sorrento Therapeutics Signs Exclusive Option to Acquire IGDRASOL
7. Sorrento Therapeutics Awarded Third Phase I STTR Grant
8. Orexigen Therapeutics Announces Upcoming Clinical Data Presentations at American Diabetes Association Annual Scientific Meeting
9. Echo Therapeutics Announces Closing of Public Offering of Common Stock And Full Exercise of Over-Allotment Option by the Underwriter
10. Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence
11. Life Technologies Signs Licensing Agreement with Suzhou Ribo Life Sciences for Development of siRNA Therapeutics in China
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... , Sept. 30, 2014  Based on ... market, Frost & Sullivan recognizes Ventana Medical Systems, ... with the 2014 North American Frost & Sullivan ... quality practices along with a focus on innovation ... global leader in tissue-based cancer diagnostic solutions for ...
(Date:9/30/2014)... YORK , Sept. 30, 2014  Proteomics ... according to a new report from Kalorama Information.  The ... deals had occurred in proteomics in the past ... IPOs, to agreements between private proteomic companies and ... companies with novel proteomics innovator companies.  Kalorama observed ...
(Date:9/30/2014)... Sept. 30, 2014   Decision Resources Group ... data, anemic chronic kidney disease non-dialysis (CKD-ND) patients ... (ESA) medication. In addition, one-year persistency is similar ... Other key findings from the report entitled ... of Erythropoiesis Stimulating Agents in Late Stage Chronic ...
Breaking Medicine Technology:Frost & Sullivan applauds the diversity of Ventana products and services for the cancer diagnostics market 2Frost & Sullivan applauds the diversity of Ventana products and services for the cancer diagnostics market 3Frost & Sullivan applauds the diversity of Ventana products and services for the cancer diagnostics market 4Report: Race for Proteomics Knowledge Spurs Investment and Partnerships 2Report: Race for Proteomics Knowledge Spurs Investment and Partnerships 3Persistency is Low for Late-Stage Anemic CKD Non-Dialysis Patients Treated with Erythropoiesis-Stimulating Agents 2Persistency is Low for Late-Stage Anemic CKD Non-Dialysis Patients Treated with Erythropoiesis-Stimulating Agents 3
(Date:9/30/2014)... September 30, 2014 Dynamic health ... hampered growth in the Bread Production industry over ... consumers to moderate their consumption of a variety ... premium varieties shrunk the market for white loaf ... proactively responded by introducing more nutritious products to ...
(Date:9/30/2014)... research team has been awarded a three-year $1.7 ... (NIH) to develop new imaging technologies and data ... how large networks of neurons in the brain ... help researchers identify the precise interactions between millions ... and speaking, and alterations in these interactions that ...
(Date:9/30/2014)... 2014 The American Diabetes Association ... diabetics curb their sweet tooth, but the most recent ... September, suggests that zero-calorie sweeteners may actually be linked ... , The Weizmann Institute of Science in Israel ... to mice, the mice developed glucose intolerance. They then ...
(Date:9/30/2014)... Tampa, FL (PRWEB) September 30, 2014 ... doors to two new clinics in Nashville, Tennessee. RMS ... Sleep Apnea Institute, and the expansion of a new ... the introduction of the Sleep Apnea Institute to Nashville, ... that suffer from sleep apnea: both diagnosed and undiagnosed. ...
(Date:9/30/2014)... News) -- Medicare should cover low-dose computed tomography lung ... disease, a coalition of more than 60 patient and ... Lung Cancer Alliance, the Society of Thoracic Surgeons, the ... the American Society of Clinical Oncology, made its point ... for Medicare & Medicaid Services (CMS). Such screening ...
Breaking Medicine News(10 mins):Health News:Bread Production in the US Industry Market Research Report from IBISWorld Has Been Updated 2Health News:Bread Production in the US Industry Market Research Report from IBISWorld Has Been Updated 3Health News:UMD receives inaugural BRAIN Initiative Award 2Health News:Artificial Sweeteners May be Linked to Greater Diabetes Risk 2Health News:Regenerative Medicine Solutions Expanding 2Health News:Groups Call for Medicare Coverage of Lung Cancer Screening 2
... Benedict XVI’s intention of soliciting a report on the acceptability ... //in exceptional cases, such as, in the event of either ... life within the precincts of marriage. ,Experts have commended ... issue such as this, while also agreeing that such an ...
... on its last lap of seeking enrollment from drug companies, and ... with three major insurance players. ,United Health Group seems to ... endorsers and a financial agreement with them to support the company. ... Medicare. ,80 companies have been in the fray with ...
... mother’s heart disease rather than the father’s tend to pose ... history of coronary disease//. ,The results of the ... American Journal of Preventive Medicine. This could help to better ... coronary problems as well as show early signs of the ...
... getting known for its severe dearth of general practitioners, further ... in the throes of a severe GP crisis. ,The ... the current trend of Doctors, gravitating to specialist sectors, which ... GP sector lean and totally understaffed. ,Dr Catherine ...
... been accused of the murder of three family members whose ... court appearance. // ,The victims were Marc Richardson, ... and a funeral visitation has been planned for them today ... Toussaint Church in Sudbury. ,The girl's boyfriend, an ...
... The World Health Organization WHO has recently released its ... // The United Nations health agency found that ... they are adequately nurtured and they claimed that the ... ,The W.H.O. says it now has scientific evidence ...
Cached Medicine News:Health News:Risk of Heart Disease Greater from Mom than Dad 2Health News:An International Growth Standard For Childs Releases By WHO 2
... 2 60-ms bursts of 50 Hz separated by .75 ... Tetanus: 50 Hz (50 pulses/s) or 100 Hz (100 ... Output Current: Adjustable from 0-70 mA , Stimulus ... Battery LED (green) indicates that the units on; it ...
Anesthesia Associates Nerve Stimulator Model AA 1050...
... newest peripheral nerve stimulator from B. Braun Medical. ... providing advanced digital technology. , ,Your ability ... allows the localization of practically all mixed nerves ... ,An additional optional component for the HNS11 is ...
... original MS-III design the new ... keypad and battery ... MS-IV peripheral nerve stimulator can ... in operating room, post anesthesia ...
Medicine Products: